Global Genome-Wide Association Studies Market Expected to Achieve 13.5% CAGR by 2029: Growth Forecast Insights

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Genome-Wide Association Studies Market Size By 2025?
The market scale for genome-wide association studies has seen exponential growth lately. The market will escalate from $1.99 billion in 2024 to $2.27 billion in 2025 with a compound annual growth rate (CAGR) of 13.8%. Certain factors such as the escalating prevalence of chronic illnesses, growing awareness of the role genes play in disease, burgeoning genomic study adoption, increased governmental funding in genomics, and the expansion of biobanks and genomic databases have all contributed to the growth during the historic period.

How Big Is the Genome-Wide Association Studies Market Size Expected to Grow by 2029?
Expectations are high for a substantial expansion in the genome-wide association studies market in the upcoming years. Estimates predict that it will achieve a size of $3.76 billion by 2029, with a compound annual growth rate (CAGR) of 13.5%. Several factors are contributing to this expected growth during the forecast period, including increased application of pharmacogenomics in clinical environments, rising embracement of multi-omics approaches, an escalating demand for personalized medicine, a surge in genomic research across different populations, and the growing development of point-of-care genetic testing. Some significant trends during this forecast period include advancements in sequencing platforms technology, novel revelations in data analysis algorithms, progression in functional genomics, research, and improvements in gene-environment interactions, and advancements in genome editing technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/genome-wide-association-studies-global-market-report

Which Key Market Drivers Powering Genome-Wide Association Studies Market Expansion and Growth?
The advancement of the genome-wide association studies marketplace is anticipated to be stoked by the rising need for personalized medicine. These personalized approaches to healthcare, which consider an individual's unique genetic makeup, lifestyle, and surroundings, allow for tailored treatment and prevention measures. This utilization of personalized medicine is rising primarily due to advancements in genomics. These advancements allow for the accurate identification of genetic variations, leading to the design of treatments personalized to specific individuals. Personalized medicinal strategies are further enhanced through genome-wide association studies (GWAS) as they identify genetic variations associated with diseases. These identified variations allow for tailored treatment strategies that offer greater insights into an individual's risk profiles and support precision therapies. For example, the Personalized Medicine Coalition (PMC), an American not-for-profit entity, reported in February 2024 that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a large increase from the 12 approved in 2022. As such, the growing need for personalized medicine plays a crucial role in the expansion of the genome-wide association studies marketplace.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28234&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Genome-Wide Association Studies Market?
Key enterprises active in the genome-wide association studies market are emphasizing on the generation of innovative solutions such as state-of-the-art research platforms to speed up the identification of diseases and the use of personalized medicine. Such a sophisticated research platform is a combined system comprised of various tools and technologies which permit the creation, analysis, and interpretation of substantial genomics data for genome-wide association studies. To illustrate, in January 2025, 23andMe Holding Co., a firm based in the USA specializing in biotechnology, introduced Discover23, a platform aimed at consumers for genetic insights and lineage exploration. This platform allows collaborators from the biopharma sector to access comprehensive genetic data, facilitated by a secure environment run by Lifebit. It offers analyses-ready genome-wide association studies (GWAS) on more than 1,000 disease cohorts, sourced from countless phenotypic data points from a large population of consenting participants. The sophisticated research platform is designed to fast-track the discovery of drugs by supporting researchers in identifying new disease biology, potential drug targets, enhancing clinical trial success rates all the while ensuring participant privacy.

What Are the Emerging Segments in the Genome-Wide Association Studies Market?
The genome-wide association studies market covered in this report is segmented as

1) By Product Type: Genotyping Services, Genotyping Kits And Reagents, Software And Data Analysis Tools, Other Product Types
2) By Application: Drug Discovery, Disease Risk Assessment, Personalized Medicine, Other Applications
3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Clinics, Other End-Users

Subsegments:
1) By Genotyping Services: Whole Genome Sequencing (Wgs), Exome Sequencing, Targeted Genotyping
2) By Genotyping Kits And Reagents: Dna Extraction Kits, Sequencing Reagents, Library Preparation Kits
3) By Software And Data Analysis Tools: Bioinformatics Platforms, Data Visualization Tools, Statistical Analysis Software
4) By Other Product Types: Sample Collection Devices, Quality Control Tools, Laboratory Consumables

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28234&type=smp

Who Are the Global Leaders in the Genome-Wide Association Studies Market?
Major companies operating in the genome-wide association studies market are F. Hoffmann-La Roche AG, AstraZeneca plc, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Eurofins Scientific SE, Laboratory Corporation of America Holdings, Daiichi Sankyo Company Limited, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Databricks Inc., Broad Institute of MIT and Harvard, BGI Genomics Co. Ltd., deCODE genetics Inc., Genomics England Ltd., CD Genomics Inc., Veritas Genetics Inc., Finngen, and The Wellcome Sanger Institute.

Which are the Top Profitable Regional Markets for the Genome-Wide Association Studies Industry?
North America was the largest region in the genome-wide association studies market in 2024. The regions covered in genome-wide association studies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28234

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.